All models were concordant with the exception of macrolides, which were not significant based on the number of grammes administered. There were no significant differences in the types of infection or the attributed mortality in either group. MRSA-infected patients had a significantly longer LOS before infection [18.8 ± ± ± ± 18.2 compared with 8.4 ± ± ± ± 6.9 (P < 0.001)] and a significantly longer post-diagnosis LOS [27.8 ± ± ± ± 32.9 compared with 18.6 ± ± ± ± 21 (P = 0.01)] than MSSA-infected patients.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen worldwide. [1] [2] [3] The Centers for Disease Control (CDC) National Nosocomial Infection Surveillance System (NNIS) reported that methicillin resistance among S. aureus in US hospitals increased from 2.4% in 1975 to 29% in 1991, with a higher degree of resistance in intensive care units. [4] [5] More recent data from 1990 through 1997 identified that the MRSA incidence rate increased 260% in hospitals that participated in the International Networks for the Study and Prevention of Emerging Antimicrobial Resistance (INSPEAR) Programme. 6 Traditionally, MRSA was identified infrequently from patients in the community, but over the last few years reports have documented increases in community MRSA, which may suggest a changing epidemiology. [7] [8] [9] [10] [11] The reasons for the emergence of MRSA are multifactorial and can be attributed to host factors, infection control practices and antimicrobial pressures. [12] [13] [14] The appearance of bacterial resistance phenotypes has been linked to the clinical use of antimicrobial agents to which the bacteria express resistance. 15 One study demonstrated that a patient's normal colonizing flora changes within 24-48 h under selective antibiotic pressures. 16 A recent review of more than 20 studies by Monnet & Frimodt-Moller 17 identified consistent associations and dose-effect relationships that support a causal relationship between MRSA and antimicrobial drug use. One of these studies demonstrated that ciprofloxacin and cephalosporins promoted the colonization and ultimately the spread of MRSA in one hospital. 18 In studies where antimicrobial classes are analysed separately both cephalosporins and fluoroquinolones are often identified as risk factors for MRSA. 19 A multi-centre study of 50 Belgian hospitals associated an increasing incidence of MRSA with increasing use of ceftazidime and cefsulodin, co-amoxiclav and fluoroquinolones. 19 Dziekan et al. 20 also showed that fluoroquinolone use was an independent risk factor for MRSA as well as nasogastric tubes and central venous catheters. In separate studies, both Crossley et al. 21 and Hershow et al. 22 noted that patients with MRSA infection had a significantly longer length of stay (LOS) before infection and were likely to have received antimicrobial therapy. A recent publication identified levofloxacin therapy, ICU setting and LOS as being independently associated with MRSA. 23 Over the past 3 years, there has been a significant increase in the incidence of nosocomial MRSA at our institution. During this time, there was no significant difference in the number of admissions or patient days. Concurrent with this increase in MRSA incidence was an increase in the usage of fluoroquinolone and β-lactam/β-lactamase inhibitor antimicrobials. The purpose of this study was to identify characteristics that were associated with nosocomial MRSA infection.
Materials and methods
This study was conducted at Albany Medical Center, a 600 bed tertiary care facility. Cases were patients infected with nosocomial MRSA from 1997 to 1999. Controls were selected randomly from a database of all patients infected with nosocomial MSSA from the same time period. A nosocomial case was defined as a patient without any evidence of infection on admission and who was culture positive >48 h after admission. A retrospective review of the patient's medical record was conducted using a standardized data collection form. All of the data were collected before MRSA or MSSA infection. Antibiotic data were grouped into antimicrobial classes for analysis. Infections were defined using the CDC NNIS definitions. 24 Crude and attributable mortality rates were calculated. Death was considered attributed to infection if the infection either directly caused death or exacerbated a pre-existing condition that otherwise would not have resulted in the patient's death. Antimicrobial susceptibility testing on S. aureus was carried out by disc diffusion according to 
Results
Univariate analysis was conducted on 121 MRSA-infected patients and 123 MSSA-infected patients from the same time period. Tables 1 and 2 list the ORs and significant levels for potential risk factors collected. MRSA-infected patients tended to have longer LOS before infection, and had more ward changes and device days. With regard to hospital location, there was a significant difference in the two units. Both the medical intensive care and rehabilitation units had a significantly higher number of patients infected with MRSA.
Patients infected with MRSA tended to have more antibiotics, particularly β-lactam antibiotics, levofloxacin and macrolides (Table 3) . Multiple logistic regression analysis identified six risk factors that were associated independently with MRSA infection. These risk factors were previous hospitalization, longer LOS before infection, surgery, enteral feedings, levofloxacin use and macrolide use. Three logistic regression models were carried out to assess antimicrobial usage. The first model included the significant β-lactam antibiotics grouped in classes, whereas the second model combined all the β-lactam antibiotics together. This was conducted because the selective pressures for all β-lactam antibiotics are approxi- mately the same, and segregating or combining them may have diluted their effect. The third model substituted the number of grammes of drug administered for significant antimicrobial agents to assess for dose-effect relationships. The results of the three models were concordant, with the exception of macrolides, which were not significant based on the number of grammes (Tables 4 and 5) . With regard to outcome, the only significant difference between MRSA-infected and MSSA-infected patients was LOS. The mean LOS for MRSA-infected patients was significantly longer (46.1 ± 38.1 compared with 26.2 ± 20.7, P < 0.001) than MSSA-infected patients. MRSA-infected patients had longer LOS before infection (18.8 ± 18.2 versus 8.4 ± 6.9, P < 0.001), and longer post-diagnosis LOS (27.8 ± 32.9 versus 18.6 ± 21, P = 0.01). There was no difference in the types of infection identified. The most common types of infection were bloodstream infections, 23.1% and 29.3% (P = 0.31); lower respiratory tract infections, 21.5% and 20.3% (P = 0.88); and pneumonia, 21.5% and 15.4% (P = 0.25), for MRSA-and MSSA-infected patients, respectively. Surgical site infections were higher in the MRSAinfected population, 12.4% versus 5.7% (P = 0.08), and soft tissue infections were higher in the MSSA-infected population, 14.6% versus 9.1% (P = 0.24). Less common infections included urinary tract infections, 5.0% and 4.1% (P = 0.77); cardiovascular system infections, 4.1% and 4.9% (P = 1.0); infections of the ears, eyes and oral cavity, 1.7% and 2.4% (P = 1.0); and infections of the reproductive system, 0.8% and 0.8% (P = 1.0), for MRSA-and MSSA-infected patients, respectively. The remaining three infections were gastrointestinal (one), and bone and joint system (two).
Although patients infected with MRSA tended to have a higher crude mortality rate, 28.9% compared with 19.5% (P = 0.10), most of these deaths were not related to infection. In a separate analysis, independent risk factors for attributed mortality were bacteraemia with an OR of 4.2 (95% CIs 1.3, 13.5), diabetes OR 3.9 (95% CIs 1.2, 12.0), kidney failure OR 4.9 (95% CIs 1.4, 16.5), steroids OR 3.5 (95% CIs 1.0, 12.1) and haemodynamic instability OR 5.7 (95% CIs 1.8, 18.7). The attributed mortality rate for MRSA-infected patients, 8.3%, was not significantly different from that of the MSSAinfected patients, 5.7% (P = 0.46). 44 postulated that the factors which predispose S. aureus to develop methicillin resistance may also predispose them to ciprofloxacin resistance. In their study, they identified an increase in ciprofloxacin resistance in isolates after using ciprofloxacin to treat MRSA infections. Although there are no known biological mechanisms for fluoroquinolones to select resistance to β-lactam antibiotics in staphylococci, evidence is mounting that fluoroquinolones exhibit some type of influence on MRSA. Ciprofloxacin resistance in MRSA developed rapidly whereas the rate of ciprofloxacin resistance in MSSA nationwide is c. 2.4%. These data indicate that there are intrinsic factors which lead to greater acquisition of fluoroquinolone resistance in MRSA. 46 Hetero-resistant S. aureus populations include sub-populations that contain the mecA gene and these resistant sub-populations can be selected for by exposure to increasing concentrations of antibiotics below MIC levels. 16 It was demonstrated that mecA-positive S. aureus strains which exhibit this hetero-resistance showed an increase in the proportion of oxacillin-resistant cells following exposure to fluoroquinolones. 47 In summary, patients infected with MRSA were more likely to have had surgery, a previous hospitalization and a longer LOS before infections. All of these factors are known to increase the probability of a patient developing an MRSA infection. The two risk factors that contributed the greatest risk for developing an MRSA infection were enteral feedings and levofloxacin as shown by their ORs and highly significant P values. Whether these two risk factors have an associated effect is unknown and beyond the scope of this analysis. Further investigation is warranted because this could lead to a modifiable practice change. The relationships between antimicrobial use and MRSA are complex and more studies that address these issues are needed. However, most studies agree that, in addition to good infection control practices, the prudent use of antimicrobial agents is one of the major steps to reducing the growing problem of antibiotic resistance. 
